AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36600308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosquito Shield™ (transfluthrin spatial repellent)
Number of subjects: 3570
Study 36600308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3570
Study 36600325 — intervention group
Group type: COMPARATOR
Intervention: Standard therapeutic education
Number of subjects: 84000
Study 36600325 — intervention group
Group type: EXPERIMENTAL
Intervention: Education using a specific application
Number of subjects: 84000
Study 36600325 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced interactive app with social features
Number of subjects: 84000
Study 36600332 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood test for lipid profile screening
Number of subjects: 3200
Study 36600353 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% subsidy for malaria rapid diagnostic tests (RDTs)
Number of subjects: 836
Study 36600353 — intervention group
Group type: EXPERIMENTAL
Intervention: Free treatment (artemisinin combination therapies (ACTs)) for positive malaria tests
Number of subjects: 836
Study 36600353 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria test result (positive vs negative)
Number of subjects: 836
Study 36600358 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAR score <2 or HEART score <4 (HEAR-T strategy)
Number of subjects: 0
Study 36600358 — intervention group
Group type: COMPARATOR
Intervention: Current recommended guidelines (control)
Number of subjects: 0
Study 36600357 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular procedures
Number of subjects: 0
Study 36600368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 44
Study 36600368 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study 36600374 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab once every 2 weeks
Number of subjects: 0
Study 36600374 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 10 mg once a week
Number of subjects: 0
Study 36600385 — intervention group
Group type: EXPERIMENTAL
Intervention: Photovoice intervention (6 weeks duration, including two photo assignments, two individual interviews, and four group meetings).
Number of subjects: 40
Study 36600385 — intervention group
Group type: EXPERIMENTAL
Intervention: Photovoice intervention (6 weeks duration).
Number of subjects: 40
Study 36600388 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated HIV/HTN care model intervention
Number of subjects: 0
Study 36600388 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 36600389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hs-TnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) measurements preoperatively and on postoperative days 1 and 2.
Number of subjects: 345
Study 36600392 — intervention group
Group type: EXPERIMENTAL
Intervention: Single CT reading by LCS-trained, AI-assisted radiologist
Number of subjects: 2400
Study 36600392 — intervention group
Group type: COMPARATOR
Intervention: Expert double reading by thoracic radiologists
Number of subjects: 2400
Study 36600392 — intervention group
Group type: EXPERIMENTAL
Intervention: AI as a stand-alone reader
Number of subjects: 2400
Study 36600425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets
Number of subjects: 430
Study 36600425 — intervention group
Group type: COMPARATOR
Intervention: Liquid-stored platelets
Number of subjects: 430
Study 36600424 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunotherapy with anakinra (recombinant interleukin-1 receptor antagonist) intravenously for patients with MALS
Number of subjects: 280
Study 36600424 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunotherapy with subcutaneous recombinant human interferon-gamma for patients with immunoparalysis
Number of subjects: 280
Study 36600424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 36600427 — intervention group
Group type: EXPERIMENTAL
Intervention: HCL-LCD (Hybrid Closed Loop system with Low Carbohydrate Diet, <130 g carbohydrate/day) for >8 months
Number of subjects: 24
Study 36600427 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes care with intermittent blinded CGM (non-HCL)
Number of subjects: 24
Study 36600428 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement (CE) activities in intervention clusters
Number of subjects: 39362
Study 36600428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CE activities)
Number of subjects: 39362
Study 36600432 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological Pupillary Index (NPi) during cardiopulmonary resuscitation
Number of subjects: 0
Study 36600432 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological Pupillary Index (NPi)
Number of subjects: 0
Study 36600432 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale (GCS)
Number of subjects: 0
Study 36600432 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin Score
Number of subjects: 0
Study 36600432 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers and neurophysiology exams
Number of subjects: 0
Study 36600534 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation followed by olaparib for 2 years
Number of subjects: 1470
Study 36600534 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemoradiation alone
Number of subjects: 1470
Study 36600534 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy with concurrent and adjuvant durvalumab for 1 year
Number of subjects: 1470
Study 36600534 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 1470
Study 36600534 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by progestin for 2 years
Number of subjects: 1470
Study 36600534 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemoradiation
Number of subjects: 1470
Study 36600535 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture alone (group A)
Number of subjects: 120
Study 36600535 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with additional manual-movement and mind-body therapies (group B)
Number of subjects: 120
Study 36600561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupadolimab (anti-CD73 antibody)
Number of subjects: 0
Study 36600670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg daily for 14 days during induction, then 45 mg daily continuously or 30 mg daily continuously with dose reduction to 15 mg daily upon achieving complete molecular response (CMR). Maintenance therapy included daily ponatinib and vincristine-prednisone monthly for 2 years, followed by daily ponatinib indefinitely. Intrathecal injections of cytarabine and methotrexate for CNS prophylaxis.
Number of subjects: 86
Study 36600670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib-related deaths from myocardial infarction in the first 37 patients treated.
Number of subjects: 86
Study 36600670 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to ponatinib and hyper-CVAD treatment.
Number of subjects: 86
Study 36601090 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 0
Study 36601119 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIC-1901 (non-cryopreserved CAR-T cells)
Number of subjects: 30
Study 36601119 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphodepletion with fludarabine and cyclophosphamide prior to CAR-T infusion
Number of subjects: 30
Study 36601119 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIC-1901 dose infused
Number of subjects: 30
Study 36601286 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Person's Face IT (YPF), an online intervention based on cognitive behavioural therapy and social skills training.
Number of subjects: 0
Study 36601889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake
Number of subjects: 800
Study 36601916 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at levels of 4, 8, 12, and 16 cm H2O
Number of subjects: 0
Study 36601916 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 36601956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan administered twice daily for 52 weeks
Number of subjects: 375
Study 36601956 — intervention group
Group type: COMPARATOR
Intervention: Enalapril administered twice daily for 52 weeks
Number of subjects: 375
Study 36601972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg/day
Number of subjects: 34
Study 36602226 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pyrotinib, letrozole, and dalpiciclib
Number of subjects: 0
Study 36602226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Number of subjects: 0
Study 36602324 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis Symptom Inventory Scale (OASIS9)
Number of subjects: 123
Study 36602324 — intervention group
Group type: EXPERIMENTAL
Intervention: OASIS9 psychometric properties
Number of subjects: 123
Study 36602619 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated online behavioral weight loss program
Number of subjects: 63
Study 36602718 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical DEX (dexamethasone)
Number of subjects: 69
Study 36602718 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical DICLO (diclofenac)
Number of subjects: 69
Study 36602718 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical DEX + DICLO (dexamethasone and diclofenac)
Number of subjects: 69
Study 36602718 — intervention group
Group type: COMPARATOR
Intervention: Topical DEX
Number of subjects: 69
Study 36602718 — intervention group
Group type: COMPARATOR
Intervention: Topical DICLO
Number of subjects: 69
Study 36602718 — intervention group
Group type: COMPARATOR
Intervention: Topical DEX + DICLO
Number of subjects: 69
Study 36602748 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 703
Study 36602796 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2)
Number of subjects: 78
Study 36602796 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) and NPC-1C (1.5 mg/kg every 2 weeks)
Number of subjects: 78
Study 36602803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Outpatient Program PE (IOP-PE)
Number of subjects: 234
Study 36602803 — intervention group
Group type: COMPARATOR
Intervention: Massed-PE
Number of subjects: 234
Study 36602803 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study 36602841 — intervention group
Group type: EXPERIMENTAL
Intervention: JITAI-MRFCBT
Number of subjects: 20
Study 36602841 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 36602846 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention treatment
Number of subjects: 160
Study 36602846 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 160
Study 36602852 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD Family Coach 1.0
Number of subjects: 200
Study 36602868 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 84
Study 36602868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 36602883 — intervention group
Group type: EXPERIMENTAL
Intervention: R-One robotic PCI system
Number of subjects: 62
Study 36602886 — intervention group
Group type: COMPARATOR
Intervention: Dance
Number of subjects: 7939
Study 36602886 — intervention group
Group type: COMPARATOR
Intervention: Aqua-based training
Number of subjects: 7939
Study 36602886 — intervention group
Group type: COMPARATOR
Intervention: Gait/balance/functional training
Number of subjects: 7939
Study 36602886 — intervention group
Group type: COMPARATOR
Intervention: Multi-domain training
Number of subjects: 7939
Study 36602886 — intervention group
Group type: COMPARATOR
Intervention: Mind-body training
Number of subjects: 7939
Study 36602886 — intervention group
Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 7939
Study 36602886 — intervention group
Group type: COMPARATOR
Intervention: Flexibility training
Number of subjects: 7939
Study 36602886 — intervention group
Group type: COMPARATOR
Intervention: Strength/resistance training
Number of subjects: 7939
Study 36602886 — intervention group
Group type: COMPARATOR
Intervention: LSVT BIG
Number of subjects: 7939
Study 36602914 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness, safety, and health program (self-administered, 30-minute sessions once a week for 12 weeks, using web-based learning modules and the Headspace app)
Number of subjects: 100
Study 36602914 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness, safety, and health program
Number of subjects: 100
Study 36602927 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation atypical antipsychotics
Number of subjects: 0
Study 36602927 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 0
Study 36602998 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion Sickness Severity Scale (MSSS)
Number of subjects: 63
Study 36603136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile App-based Coping Skills Training
Number of subjects: 0
Study 36603136 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36603135 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36603167 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention, details not available
Number of subjects: 0
Study 36603167 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 36603175 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with gemcitabine and split-dose cisplatin (GC)
Number of subjects: 57
Study 36603187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiation therapy (CRT) delivered to 90.8% of participants in AALL0434
Number of subjects: 2164
Study 36603187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy without CRT in AALL1231, delivered to 88.2% of participants
Number of subjects: 2164
Study 36603187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelarabine on AALL0434
Number of subjects: 2164
Study 36603187 — intervention group
Group type: COMPARATOR
Intervention: CNS-3 status with CRT
Number of subjects: 2164
Study 36603187 — intervention group
Group type: COMPARATOR
Intervention: CNS-1 and CNS-2 status at diagnosis
Number of subjects: 2164
Study 36603202 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 941
Study 36603202 — intervention group
Group type: COMPARATOR
Intervention: Delayed pushing
Number of subjects: 941
Study 36603216 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-dependent electrical stimulation of afferent pathways
Number of subjects: 0
Study 36603460 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 573
Study 36603460 — intervention group
Group type: COMPARATOR
Intervention: Usual care nutrition
Number of subjects: 573
Study 36603478 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA analyzed using ElucidVivo (Elucid Bioimaging Inc.)
Number of subjects: 576
Study 36603478 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic correlates
Number of subjects: 576
Study 36603566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1073
Study 36603566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073
Study 36603963 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformer pilates exercises (2 times a week for 6 weeks)
Number of subjects: 28
Study 36603963 — intervention group
Group type: COMPARATOR
Intervention: Home mat pilates exercises (2 times a week for 6 weeks)
Number of subjects: 28
Study 36604128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloth mask
Number of subjects: 72
Study 36604128 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 72
Study 36604128 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP3 mask
Number of subjects: 72
Study 36604128 — intervention group
Group type: COMPARATOR
Intervention: No mask
Number of subjects: 72
Study 36604128 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask wearing during exercise
Number of subjects: 72
Study 36604127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and cisplatin administered via pressurised intraperitoneal aerosol chemotherapy (PIPAC)
Number of subjects: 0
Study 36604153 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 0
Study 36604156 — intervention group
Group type: EXPERIMENTAL
Intervention: AUTO BFR training
Number of subjects: 56
Study 36604156 — intervention group
Group type: COMPARATOR
Intervention: NAUTO BFR training
Number of subjects: 56
Study 36604240 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss clinical trial
Number of subjects: 110
Study 36604240 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and healthy food choices
Number of subjects: 110
Study 36604240 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting U.S. guidelines for MVPA and FVI
Number of subjects: 110
Study 36604262 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 60,000 IU monthly
Number of subjects: 5670
Study 36604262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5670
Study 36604372 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking ability evaluated with the 3-Meter Back Walk Test (3MBWT)
Number of subjects: 30
Study 36604372 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Control Measurement Scale (TCMS)
Number of subjects: 30
Study 36604372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gillette Functional Assessment Questionnaire (FAQ)
Number of subjects: 30
Study 36604372 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MBWT
Number of subjects: 30
Study 36604372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip extension proprioception
Number of subjects: 30
Study 36604372 — intervention group
Group type: EXPERIMENTAL
Intervention: FAQ
Number of subjects: 30
Study 36604685 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking Healthy Programme - Brief Group version (THP-BGV) delivered in five online sessions by antenatal nurses.
Number of subjects: 88
Study 36604685 — intervention group
Group type: COMPARATOR
Intervention: Usual care consisting of routine online educational pregnancy classes aided by antenatal nurses.
Number of subjects: 88
Study 36604714 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed learning (online access to program materials)
Number of subjects: 0
Study 36604714 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated learning (includes live webinars)
Number of subjects: 0
Study 36604756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus and adjunct aflibercept (combination)
Number of subjects: 20
Study 36604756 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept monotherapy (control)
Number of subjects: 20
Study 36605275 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 0
Study 36605275 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 36605436 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (PD-L1 antibody) combined with FOLFOX chemotherapy and cetuximab (anti-EGFR antibody)
Number of subjects: 43
Study 36605436 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab, FOLFOX, and cetuximab
Number of subjects: 43
Study 36606005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity psychosocial telemental maternal intervention
Number of subjects: 58
Study 36606005 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 36606032 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital therapeutic intervention (DTxP)
Number of subjects: 0
Study 36606032 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36606049 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT at baseline and month 3 (M3)
Number of subjects: 52
Study 36606049 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 52
Study 36606049 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PET/CT
Number of subjects: 52
Study 36606059 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D full health state (FHS) after therapeutic intervention
Number of subjects: 147
Study 36606059 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of EQ-5D-3L FHS and 'no problems' in mobility after therapeutic intervention
Number of subjects: 147
Study 36606059 — intervention group
Group type: COMPARATOR
Intervention: No FHS respondents
Number of subjects: 147
Study 36606100 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA regimen (direct-acting antiviral treatment); 8 patients started treatment
Number of subjects: 12500
Study 36606100 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 12500
Study 36606100 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12500
Study 36606131 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive anti-stigma intervention
Number of subjects: 0
Study 36606308 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent mask wearing
Number of subjects: 3903
Study 36606308 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvaccinated individuals
Number of subjects: 3903
Study 36606308 — intervention group
Group type: EXPERIMENTAL
Intervention: Not wearing a mask
Number of subjects: 3903
Study 36606308 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvaccinated and not wearing a mask
Number of subjects: 3903
Study 36606308 — intervention group
Group type: COMPARATOR
Intervention: Always wearing a mask and vaccinated (≥14 days after mRNA vaccination)
Number of subjects: 3903
Study 36606536 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg administered subcutaneously for 52 weeks
Number of subjects: 160
Study 36606536 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band ultraviolet B (nb-UVB) phototherapy
Number of subjects: 160
Study 36606571 — intervention group
Group type: EXPERIMENTAL
Intervention: CH-EUS MASTER guided EUS-FNA
Number of subjects: 0